Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
出版年份 2022 全文链接
标题
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
作者
关键词
Advanced prostate cancer, Hormone-sensitive prostate cancer, Castration-resistant prostate cancer, Prostate cancer treatment, Imaging, Genetics, Tumour genomic profiling, Next-generation sequencing, Lu-PSMA therapy, PARP inhibition
出版物
EUROPEAN UROLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-04-18
DOI
10.1016/j.eururo.2022.04.002
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
- (2021) Vedang Murthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Mary B. Daly et al. Journal of the National Comprehensive Cancer Network
- Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
- (2021) Tamara L. Lotan et al. MODERN PATHOLOGY
- UpFrontPSMA: A Randomised Phase 2 Study of Sequential 177 Lu‐PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone‐Naïve Prostate Cancer
- (2021) Nattakorn Dhiantravan et al. BJU INTERNATIONAL
- E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
- (2021) Francesco Ceci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer
- (2021) Simona Malaspina et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.
- (2021) Nobuaki Matsubara et al. JOURNAL OF CLINICAL ONCOLOGY
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- Radiotherapy of oligometastatic prostate cancer: a systematic review
- (2021) Paul Rogowski et al. Radiation Oncology
- Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer
- (2021) Adnan Ali et al. JAMA Oncology
- Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer
- (2021) Rebeca Lozano et al. EUROPEAN JOURNAL OF CANCER
- Metastatic Prostate Cancer: In Search of More Granularity
- (2021) Alok K. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
- (2021) G. Attard et al. ANNALS OF ONCOLOGY
- LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
- (2021) K. Fizazi et al. ANNALS OF ONCOLOGY
- Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis
- (2021) Hongyan Cheng et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901)
- (2021) Louise Emmett et al. BJU INTERNATIONAL
- Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
- (2021) Renato D. Lopes et al. CIRCULATION
- Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer
- (2021) David A. Pattison et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
- (2021) Johann S de Bono et al. LANCET ONCOLOGY
- Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
- (2021) Andrei Gafita et al. LANCET ONCOLOGY
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
- (2021) Daniel Groener et al. EJNMMI Research
- Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection
- (2021) Thomas A. Hope et al. JAMA Oncology
- The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
- (2021) N.Y.L. Ngoi et al. ESMO Open
- Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer
- (2021) Yawei Li et al. iScience
- Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
- (2021) Ursula M. Vogl et al. EUROPEAN JOURNAL OF CANCER
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
- (2020) Wassim Abida et al. CLINICAL CANCER RESEARCH
- Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations
- (2020) Zsofia Sztupinszki et al. CLINICAL CANCER RESEARCH
- New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide
- (2020) Florian Rosar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
- (2020) Silke Gillessen et al. EUROPEAN UROLOGY
- Knowing what’s growing: Why ductal and intraductal prostate cancer matter
- (2020) Mitchell G. Lawrence et al. Science Translational Medicine
- PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review
- (2020) Lars J. Petersen et al. CANCER IMAGING
- Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
- (2020) Michael S Hofman et al. LANCET
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
- (2020) Neal D. Shore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
- (2020) Ryan Phillips et al. JAMA Oncology
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) C. Parker et al. ANNALS OF ONCOLOGY
- Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study
- (2020) Andrei Gafita et al. EUROPEAN UROLOGY
- When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities
- (2020) Nora Sundahl et al. EUROPEAN UROLOGY
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
- (2020) Philip Cornford et al. EUROPEAN UROLOGY
- Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?
- (2020) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
- (2020) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
- (2020) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer
- (2020) Stephen E. Lincoln et al. JAMA Network Open
- Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference
- (2020) Kendal Jensen et al. JAMA Oncology
- Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
- (2020) Antje Neeb et al. EUROPEAN UROLOGY
- Going nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team
- (2019) Declan G Murphy et al. BJU INTERNATIONAL
- Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution
- (2019) Gonçalo Ferreira et al. CANCER IMAGING
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Matched-pair comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy
- (2019) Isabel Rauscher et al. JOURNAL OF NUCLEAR MEDICINE
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
- (2019) Alex P. Hoyle et al. EUROPEAN UROLOGY
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
- (2019) N W Clarke et al. ANNALS OF ONCOLOGY
- TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
- (2019) Michael S. Hofman et al. BJU INTERNATIONAL
- Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
- (2019) John Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations
- (2018) René Böttcher et al. BMC CANCER
- Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial
- (2018) Shankar Siva et al. EUROPEAN UROLOGY
- Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
- (2018) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
- (2018) Silke Gillessen et al. EUROPEAN UROLOGY
- Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
- (2018) Veda N. Giri et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- (2018) Christos E. Kyriakopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
- (2018) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
- (2018) Piet Ost et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
- (2018) Liselotte M.S. Boevé et al. EUROPEAN UROLOGY
- Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
- (2018) Anna Yordanova et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Early experience of rechallenge 177Lu-PSMA radioligand therapy after an initial good response in patients with mCRPC
- (2018) Andrei Gafita et al. JOURNAL OF NUCLEAR MEDICINE
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
- (2018) Christopher C Parker et al. LANCET
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum sensitivity in metastatic prostate cancer: does histology matter?
- (2017) Michael S. Humeniuk et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
- (2016) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
- (2015) S. Gillessen et al. ANNALS OF ONCOLOGY
- Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis
- (2015) Gail P. Risbridger et al. EUROPEAN UROLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
- (2013) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer
- (2010) Matthew R. Smith et al. JOURNAL OF UROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search